DSGN•benzinga•
Design Therapeutics Expects Cash And Equivalents Of $245.5M As Of December 31, 2024, To Fund Its Planned Operating Expenses Into 2029
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga